{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:35:13Z","timestamp":1790267713378,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2015_A130"],"award-info":[{"award-number":["2015_A130"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TH-784\/2-1"],"award-info":[{"award-number":["TH-784\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TH-784\/2-2"],"award-info":[{"award-number":["TH-784\/2-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["\u2018Aging"],"award-info":[{"award-number":["\u2018Aging"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001656","name":"Helmholtz-Gemeinschaft","doi-asserted-by":"publisher","award":["Metabolic Programming, AMPro\u2019"],"award-info":[{"award-number":["Metabolic Programming, AMPro\u2019"]}],"id":[{"id":"10.13039\/501100001656","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tethys Bioscience Inc.","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]},{"DOI":"10.13039\/100016946","name":"Singulex","doi-asserted-by":"crossref","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100016946","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biomarkers may contribute to our understanding of the pathophysiology of various diseases. Type 2 diabetes (T2D) and coronary heart disease (CHD) share many clinical and lifestyle risk factors and several biomarkers are associated with both diseases. The current analysis aims to assess the relevance of biomarkers combined to pathway groups for the development of T2D and CHD in the same cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-seven serum biomarkers were measured in the MONICA\/KORA case-cohort study using clinical chemistry assays and ultrasensitive molecular counting technology. The T2D (CHD) analyses included 689 (568) incident cases and 1850 (2004) non-cases from three population-based surveys. At baseline, the study participants were 35\u201374\u00a0years old. The median follow-up was 14\u00a0years. We computed Cox regression models for each biomarker, adjusted for age, sex, and survey. Additionally, we assigned the biomarkers to 19 etiological pathways based on information from literature. One age-, sex-, and survey-controlled average variable was built for each pathway. We used the R<jats:sup>2<\/jats:sup><jats:sub>PM<\/jats:sub> coefficient of determination to assess the explained disease risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The associations of many biomarkers, such as several cytokines or the iron marker soluble transferrin receptor (sTfR), were similar in strength for T2D and CHD, but we also observed important differences. Lipoprotein (a) (Lp(a)) and N-terminal pro B-type natriuretic peptide (NT-proBNP) even demonstrated opposite effect directions. All pathway variables together explained 49% of the T2D risk and 21% of the CHD risk. The insulin-like growth factor binding protein 2 (IGFBP-2, IGF\/IGFBP system pathway) best explained the T2D risk (about 9% explained risk, independent of all other pathway variables). For CHD, the myocardial-injury- and lipid-related-pathways were most important and both explained about 4% of the CHD risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The biomarker-derived pathway variables explained a higher proportion of the T2D risk compared to CHD. The ranking of the pathways differed between the two diseases, with the IGF\/IGFBP-system-pathway being most strongly associated with T2D and the myocardial-injury- and lipid-related-pathways with CHD. Our results help to better understand the pathophysiology of the two diseases, with the ultimate goal of pointing out targets for lifestyle intervention and drug development to ideally prevent both T2D and CHD development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01003-w","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:40:42Z","timestamp":1583991642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease\u2014a comparison in the MONICA\/KORA study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-433X","authenticated-orcid":false,"given":"Cornelia","family":"Huth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Zierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sudduth-Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-6544","authenticated-orcid":false,"given":"Christa","family":"Meisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-0985","authenticated-orcid":false,"given":"Annette","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-093X","authenticated-orcid":false,"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-6440","authenticated-orcid":false,"given":"Barbara","family":"Thorand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"M Naghavi","year":"2015","unstructured":"Naghavi M, Wang HD, Lozano R, Davis A, Liang XF, Zhou MG, Vollset SE, Ozgoren AA, Abdalla S, Abd-Allah F, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol."},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2337\/dc16-0614","volume":"39","author":"JM Baena-Diez","year":"2016","unstructured":"Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, Guembe MJ, Rigo F, Tormo-Diaz MJ, Moreno-Iribas C, et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 2016;39:1987\u201395.","journal-title":"Diabetes Care"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.290.7.898","volume":"290","author":"UN Khot","year":"2003","unstructured":"Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898\u2013904.","journal-title":"JAMA"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archinte.162.1.82","volume":"162","author":"C Meisinger","year":"2002","unstructured":"Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, Lowel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med. 2002;162:82\u20139.","journal-title":"Arch Intern Med"},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"e19852","DOI":"10.1371\/journal.pone.0019852","volume":"6","author":"C Herder","year":"2011","unstructured":"Herder C, Baumert J, Zierer A, Roden M, Meisinger C, Karakas M, Chambless L, Rathmann W, Peters A, Koenig W, Thorand B. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA\/KORA Augsburg case-cohort study. PLoS ONE. 2011;6:e19852.","journal-title":"PLoS ONE"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:122.","journal-title":"Cardiovasc Diabetol."},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/diab.44.4.369","volume":"44","author":"MP Stern","year":"1995","unstructured":"Stern MP. Diabetes and cardiovascular disease. The \u201ccommon soil\u201d hypothesis. Diabetes. 1995;44:369\u201374.","journal-title":"Diabetes."},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"e011581","DOI":"10.1161\/JAHA.118.011581","volume":"8","author":"SU Khan","year":"2019","unstructured":"Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, Kaluski E, Lincoff AM, Martin SS, Blaha MJ. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e011581.","journal-title":"J Am Heart Assoc."},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"e0163721","DOI":"10.1371\/journal.pone.0163721","volume":"11","author":"A Abbasi","year":"2016","unstructured":"Abbasi A, Sahlqvist AS, Lotta L, Brosnan JM, Vollenweider P, Giabbanelli P, Nunez DJ, Waterworth D, Scott RA, Langenberg C, Wareham NJ. A systematic review of biomarkers and risk of incident type 2 diabetes: an overview of epidemiological, prediction and aetiological research literature. PLoS ONE. 2016;11:e0163721.","journal-title":"PLoS ONE"},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrendo.2014.155","volume":"10","author":"MK Jensen","year":"2014","unstructured":"Jensen MK, Bertoia ML, Cahill LE, Agarwal I, Rimm EB, Mukamal KJ. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol. 2014;10:659\u201372.","journal-title":"Nat Rev Endocrinol."},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/EJE-15-0631","volume":"173","author":"C Huth","year":"2015","unstructured":"Huth C, Beuerle S, Zierer A, Heier M, Herder C, Kaiser T, Koenig W, Kronenberg F, Oexle K, Rathmann W, Roden M, Schwab S, Seissler J, Stockl D, Meisinger C, Peters A, Thorand B. Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: the KORA F4 study. Eur J Endocrinol. 2015;173:643\u201353.","journal-title":"Eur J Endocrinol"},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3945\/jn.108.097766","volume":"138","author":"Q Sun","year":"2008","unstructured":"Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138:2436\u201341.","journal-title":"J Nutr"},{"key":"1003_CR14","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.2337\/dc11-0775","volume":"34","author":"B Thorand","year":"2011","unstructured":"Thorand B, Zierer A, Huth C, Linseisen J, Meisinger C, Roden M, Peters A, Koenig W, Herder C. Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: results from the MONICA\/KORA Augsburg study. Diabetes Care. 2011;34:2320\u20132.","journal-title":"Diabetes Care"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/EJE-17-1053","volume":"178","author":"C Sujana","year":"2018","unstructured":"Sujana C, Huth C, Zierer A, Meesters S, Sudduth-Klinger J, Koenig W, Herder C, Peters A, Thorand B. Association of fetuin-A with incident type 2 diabetes: results from the MONICA\/KORA Augsburg study and a systematic meta-analysis. Eur J Endocrinol. 2018;178:389\u201398.","journal-title":"Eur J Endocrinol"},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1464-5491.2010.03043.x","volume":"27","author":"B Thorand","year":"2010","unstructured":"Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin\/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: results from the MONICA\/KORA Augsburg study 1984-2002. Diabet Med. 2010;27:1004\u201311.","journal-title":"Diabet Med"},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10654-017-0266-7","volume":"32","author":"BM Kaess","year":"2017","unstructured":"Kaess BM, de Las Heras Gala T, Zierer A, Meisinger C, Wahl S, Peters A, Todd J, Herder C, Huth C, Thorand B, Koenig W. Ultra-sensitive troponin I is an independent predictor of incident coronary heart disease in the general population. Eur J Epidemiol. 2017;32:583\u201391.","journal-title":"Eur J Epidemiol"},{"key":"1003_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1210\/jc.2012-2368","volume":"98","author":"M Karakas","year":"2013","unstructured":"Karakas M, Thorand B, Zierer A, Huth C, Meisinger C, Roden M, Rottbauer W, Peters A, Koenig W, Herder C. Low levels of serum 25-hydroxyvitamin D are associated with increased risk of myocardial infarction, especially in women: results from the MONICA\/KORA Augsburg case-cohort study. J Clin Endocrinol Metab. 2013;98:272\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"1003_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.atherosclerosis.2009.08.020","volume":"209","author":"M Karakas","year":"2010","unstructured":"Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, Koenig W, Thorand B. Leptin, adiponectin, their ratio and risk of coronary heart disease: results from the MONICA\/KORA Augsburg study 1984\u20132002. Atherosclerosis. 2010;209:220\u20135.","journal-title":"Atherosclerosis."},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/ATVBAHA.117.309307","volume":"37","author":"C Herder","year":"2017","unstructured":"Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kuulasmaa K, Peretz D, Ligthart S, et al. Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol. 2017;37:1222\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1003_CR21","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.2337\/diabetes.54.10.2932","volume":"54","author":"B Thorand","year":"2005","unstructured":"Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes\u2014results from the MONICA\/KORA Augsburg study, 1984-2002. Diabetes. 2005;54:2932\u20138.","journal-title":"Diabetes"},{"key":"1003_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/01.CIR.90.1.583","volume":"90","author":"H Tunstall-Pedoe","year":"1994","unstructured":"Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583\u2013612.","journal-title":"Circulation"},{"key":"1003_CR23","volume-title":"The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification","author":"RJC Prineas","year":"1982","unstructured":"Prineas RJC, Crow RS, Blackburn HW. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston: Wright; 1982."},{"key":"1003_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","volume":"36","author":"JS Alpert","year":"2000","unstructured":"Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined\u2013a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0895-4356(91)90036-9","volume":"44","author":"H Lowel","year":"1991","unstructured":"Lowel H, Lewis M, Hormann A, Keil U. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol. 1991;44:249\u201360.","journal-title":"J Clin Epidemiol"},{"key":"1003_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12874-016-0239-7","volume":"16","author":"S Wahl","year":"2016","unstructured":"Wahl S, Boulesteix AL, Zierer A, Thorand B, de Wiel MA. Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation. BMC Med Res Methodol. 2016;16:144.","journal-title":"BMC Med Res Methodol"},{"key":"1003_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","volume":"18","author":"S van Buuren","year":"1999","unstructured":"van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681\u201394.","journal-title":"Stat Med"},{"key":"1003_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"key":"1003_CR29","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2014."},{"key":"1003_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","volume":"9","author":"A Marshall","year":"2009","unstructured":"Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.","journal-title":"BMC Med Res Methodol"},{"key":"1003_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1037\/0021-9010.72.1.146","volume":"72","author":"NC Silver","year":"1987","unstructured":"Silver NC, Dunlap WP. Averaging correlation coefficients: should Fisher\u2019s z transformation be used? J Appl Psychol. 1987;72:146\u20138.","journal-title":"J Appl Psychol"},{"key":"1003_CR32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0895-4356(99)00102-X","volume":"52","author":"WE Barlow","year":"1999","unstructured":"Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52:1165\u201372.","journal-title":"J Clin Epidemiol"},{"key":"1003_CR33","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2307\/2533444","volume":"50","author":"WE Barlow","year":"1994","unstructured":"Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064\u201372.","journal-title":"Biometrics"},{"key":"1003_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987."},{"key":"1003_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/biomet\/75.3.525","volume":"75","author":"JT Kent","year":"1988","unstructured":"Kent JT, O\u2019Quigley J. Measures of dependence for censored survival data. Biometrika. 1988;75:525\u201334.","journal-title":"Biometrika"},{"key":"1003_CR36","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1002\/sim.4242","volume":"31","author":"B Choodari-Oskooei","year":"2012","unstructured":"Choodari-Oskooei B, Royston P, Parmar MK. A simulation study of predictive ability measures in a survival model I: explained variation measures. Stat Med. 2012;31:2627\u201343.","journal-title":"Stat Med"},{"key":"1003_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1194\/jlr.C085639","volume":"59","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S. In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes. J Lipid Res. 2018;59:741\u20134.","journal-title":"J Lipid Res"},{"key":"1003_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","volume":"16","author":"E Paige","year":"2017","unstructured":"Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.","journal-title":"Cardiovasc Diabetol."},{"key":"1003_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","volume":"30","author":"F Kronenberg","year":"2016","unstructured":"Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30:87\u2013100.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1003_CR40","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, Bjornsson E, Norddahl GL, Jonasdottir A, Jonasdottir A, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"1003_CR41","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","volume":"63","author":"A Tolbus","year":"2017","unstructured":"Tolbus A, Mortensen MB, Nielsen SF, Kamstrup PR, Bojesen SE, Nordestgaard BG. Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with Kringle IV type 2 repeats. Clin Chem. 2017;63:1866\u201376.","journal-title":"Clin Chem"},{"key":"1003_CR42","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1194\/jlr.P082792","volume":"59","author":"DL Mu-Han-Ha-Li","year":"2018","unstructured":"Mu-Han-Ha-Li DL, Zhai TY, Ling Y, Gao X. LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk. J Lipid Res. 2018;59:884\u201391.","journal-title":"J Lipid Res"},{"key":"1003_CR43","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1007\/s00125-015-3762-x","volume":"58","author":"C Andersson","year":"2015","unstructured":"Andersson C, Lyass A, Larson MG, Robins SJ, Vasan RS. Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study. Diabetologia. 2015;58:2774\u201380.","journal-title":"Diabetologia"},{"key":"1003_CR44","doi-asserted-by":"publisher","first-page":"e1002642","DOI":"10.1371\/journal.pmed.1002642","volume":"15","author":"Q Feng","year":"2018","unstructured":"Feng Q, Wei WQ, Chung CP, Levinson RT, Sundermann AC, Mosley JD, Bastarache L, Ferguson JF, Cox NJ, Roden DM, Denny JC, Linton MF, Edwards DRV, Stein CM. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: a US-based cross-sectional observational study using electronic health records. PLoS Med. 2018;15:e1002642.","journal-title":"PLoS Med."},{"key":"1003_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316:1383\u201391.","journal-title":"JAMA"},{"key":"1003_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-018-0738-4","volume":"17","author":"MF van Stee","year":"2018","unstructured":"van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 2018;17:94.","journal-title":"Cardiovasc Diabetol."},{"key":"1003_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0125-x","author":"RAJ Smit","year":"2019","unstructured":"Smit RAJ, Trompet S, Leong A, Goodarzi MO, Postmus I, Warren H, Theusch E, Barnes MR, Arsenault BJ, Li X et al. Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. Pharmacogenomics J. 2019.  https:\/\/doi.org\/10.1038\/s41397-019-0125-x.","journal-title":"Pharmacogenomics J"},{"key":"1003_CR48","doi-asserted-by":"publisher","first-page":"e1001112","DOI":"10.1371\/journal.pmed.1001112","volume":"8","author":"R Pfister","year":"2011","unstructured":"Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C, Wareham NJ. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8:e1001112.","journal-title":"PLoS Med."},{"key":"1003_CR49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/obr.12598","volume":"18","author":"K Verboven","year":"2017","unstructured":"Verboven K, Hansen D, Jocken JWE, Blaak EE. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity. Obes Rev. 2017;18:1243\u201359.","journal-title":"Obes Rev"},{"key":"1003_CR50","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","volume":"4","author":"P Willeit","year":"2016","unstructured":"Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016;4:840\u20139.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1003_CR51","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.2337\/db11-1488","volume":"61","author":"SN Rajpathak","year":"2012","unstructured":"Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012;61:2248\u201354.","journal-title":"Diabetes"},{"key":"1003_CR52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.molmet.2018.10.008","volume":"19","author":"NJ Haywood","year":"2019","unstructured":"Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor and binding protein family: novel therapeutic targets in obesity & diabetes. Mol Metab. 2019;19:86\u201396.","journal-title":"Mol Metab."},{"key":"1003_CR53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2337\/db18-0620","volume":"68","author":"C Wittenbecher","year":"2019","unstructured":"Wittenbecher C, Ouni M, Kuxhaus O, Jahnert M, Gottmann P, Teichmann A, Meidtner K, Kriebel J, Grallert H, Pischon T, Boeing H, Schulze MB, Schurmann A. Insulin-like growth factor binding protein 2 (IGFBP-2) and the risk of developing type 2 diabetes. Diabetes. 2019;68:188\u201397.","journal-title":"Diabetes"},{"key":"1003_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/ATVBAHA.118.311928","volume":"39","author":"RV Shah","year":"2019","unstructured":"Shah RV, Hwang SJ, Yeri A, Tanriverdi K, Pico AR, Yao C, Murthy V, Ho J, Vitseva O, Demarco D, Shah S, Iafrati MD, Levy D, Freedman JE. Proteins altered by surgical weight loss highlight biomarkers of insulin resistance in the community. Arterioscler Thromb Vasc Biol. 2019;39:107\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1003_CR55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41598-018-36512-y","volume":"9","author":"J Molvin","year":"2019","unstructured":"Molvin J, Pareek M, Jujic A, Melander O, Rastam L, Lindblad U, Daka B, Leosdottir M, Nilsson PM, Olsen MH, Magnusson M. Using a targeted proteomics chip to explore pathophysiological pathways for incident diabetes\u2014The Malmo Preventive Project. Sci Rep. 2019;9:272.","journal-title":"Sci Rep."},{"key":"1003_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1530\/EJE-18-0422","volume":"180","author":"AW van den Beld","year":"2019","unstructured":"van den Beld AW, Carlson OD, Doyle ME, Rizopoulos D, Ferrucci L, van der Lely AJ, Egan JM. IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population. Eur J Endocrinol. 2019;180:109\u201316.","journal-title":"Eur J Endocrinol"},{"key":"1003_CR57","doi-asserted-by":"publisher","first-page":"3035184","DOI":"10.1155\/2017\/3035184","volume":"2017","author":"B Assefa","year":"2017","unstructured":"Assefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM. Insulin-like growth factor (IGF) binding protein-2, independently of IGF-1, induces GLUT-4 translocation and glucose uptake in 3T3-L1 adipocytes. Oxid Med Cell Longev. 2017;2017:3035184.","journal-title":"Oxid Med Cell Longev."},{"key":"1003_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/j.1532-5415.2009.02318.x","volume":"57","author":"D Hu","year":"2009","unstructured":"Hu D, Pawlikowska L, Kanaya A, Hsueh WC, Colbert L, Newman AB, Satterfield S, Rosen C, Cummings SR, Harris TB, Ziv E, Health, Aging, and Body Composition Study. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the health, aging, and body composition study. J Am Geriatr Soc. 2009;57:1213\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"1003_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1530\/EJE-12-0160","volume":"167","author":"AW van den Beld","year":"2012","unstructured":"van den Beld AW, Blum WF, Brugts MP, Janssen JA, Grobbee DE, Lamberts SW. High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. Eur J Endocrinol. 2012;167:111\u20137.","journal-title":"Eur J Endocrinol"},{"key":"1003_CR60","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/jcm8122033","volume":"8","author":"L Bourebaba","year":"2019","unstructured":"Bourebaba L, Marycz K. Pathophysiological implication of Fetuin-A glycoprotein in the development of metabolic disorders: a concise review. J Clin Med. 2019;8:2033.","journal-title":"J Clin Med."},{"key":"1003_CR61","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.118.038772","volume":"139","author":"X Jia","year":"2019","unstructured":"Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM. High-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139:2642\u201353.","journal-title":"Circulation"},{"key":"1003_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10654-010-9539-0","volume":"26","author":"J Montonen","year":"2011","unstructured":"Montonen J, Drogan D, Joost HG, Boeing H, Fritsche A, Schleicher E, Schulze MB, Pischon T. Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur J Epidemiol. 2011;26:29\u201338.","journal-title":"Eur J Epidemiol"},{"key":"1003_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11892-018-1021-5","volume":"18","author":"RJ Strawbridge","year":"2018","unstructured":"Strawbridge RJ, van Zuydam NR. Shared genetic contribution of type 2 diabetes and cardiovascular disease: implications for prognosis and treatment. Curr Diab Rep. 2018;18:59.","journal-title":"Curr Diab Rep."},{"key":"1003_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12933-019-0930-1","volume":"18","author":"Q Zheng","year":"2019","unstructured":"Zheng Q, Jiang J, Huo Y, Chen D. Genetic predisposition to type 2 diabetes is associated with severity of coronary artery disease in patients with acute coronary syndromes. Cardiovasc Diabetol. 2019;18:131.","journal-title":"Cardiovasc Diabetol."},{"key":"1003_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-018-0733-9","volume":"17","author":"X Bao","year":"2018","unstructured":"Bao X, Borne Y, Johnson L, Muhammad IF, Persson M, Niu K, Engstrom G. Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the \u2018common soil\u2019 hypothesis. Cardiovasc Diabetol. 2018;17:87.","journal-title":"Cardiovasc Diabetol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01003-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:44:09Z","timestamp":1615509849000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01003-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01003-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies were approved by the local authorities and carried out in accordance with the Declaration of Helsinki. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WK has received personal fees for consulting and lectures from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor, Kowa, Amgen, Corvidia, Berlin-Chemie, and Sanofi, and non-financial support from Beckmann, Singulex, Abbott, and Roche Diagnostics. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}